Share

EORTC embarked on a membership renewal programme

In 2020, EORTC embarked on an ambitious membership renewal programme, in order to comply with GDPR regulation and to ensure that all information of its members are up to date. Following this renewal programme, EORTC can confirm over 2800 direct members coming from 730 institutions. The network comprises of members coming from 48 countries around the world, with the top ten from Europe.

Countries of EORTC members - graph

EORTC is a truly multidisciplinary organisation of which 15% are organ specialists. Its membership spans over 30 different disciplines conducting clinical research.

EORTC members profile - graph

“One of the uniqueness of EORTC is that we conduct trials across multiple tumours and the members are stratified across groups related to their tumour of interest. We are able to attract leading clinical researchers across the globe, conducting practice changing trials,” said Denis Lacombe, EORTC Director General. “As EORTC approaches its 60th anniversary next year, we remain fully committed to all cancer patients, our members, partners and supporters, ensuring the organisation stays true to its mission and paves the way to innovation in cancer care.”

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023